Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-a-co-producing T cell-mediated antitumor immunity
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, I-K | - |
dc.contributor.author | Li, Y. | - |
dc.contributor.author | Oh, E. | - |
dc.contributor.author | Yun, C-O | - |
dc.date.accessioned | 2021-08-03T11:34:19Z | - |
dc.date.available | 2021-08-03T11:34:19Z | - |
dc.date.created | 2021-07-26 | - |
dc.date.issued | 2013-10-25 | - |
dc.identifier.issn | 1043-0342 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/46405 | - |
dc.description.abstract | Cytokine immunogene therapy is a promising strategy for cancer treatment. Interleukin (IL)-12 boosts potent antitumor immunity by inducing Th 1 cell differentiation and stimulating cytotoxic T lymphocyte and natural killer cell cytotoxicity. IL-23 has been proposed to have similar but not overlapping functions with IL-12 in inducing Th1 cell differentiation and antitumor immunity. However, the therapeutic effects of intratumoral co-expression of IL-12 and IL-23 in a cancer model have yet to be investigated. Therefore, we investigated for the first time an effective cancer immunogene therapy of syngeneic tumors via intratumoral inoculation of oncolytic adenovirus co-expressing IL-23 and p35, RdB/IL23/p35. Intratumoral administration of RdB/IL23/p35 elicited strong antitumor effects and increased survival in a murine B16-F10 syngeneic tumor model. The levels of IL-12, IL-23, interferon-γ (IFN-γ), and tumor necrosis factor-a (TNF-a) were elevated in RdB/IL23/p35-treated tumors. Moreover, the proportion of regulatory T cells was markedly decreased in mice treated with RdB/IL23/p35. Consistent with these data, mice injected with RdB/IL23/p35 showed massive infiltration of CD4 and CD8 T cells into the tumor as well as enhanced induction of tumor-specific immunity. Importantly, therapeutic mechanism of antitumor immunity mediated by RdB/IL23/p35 is associated with the generation and recruitment of IFN-γ- and TNF-a-co-producing T cells in tumor microenvironment. These results provide a new insight into therapeutic mechanisms of IL-12 plus IL-23 and provide a potential clinical cancer immunotherapeutic agent for improved antitumor immunity. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MARY ANN LIEBERT, INC | - |
dc.title | Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-a-co-producing T cell-mediated antitumor immunity | - |
dc.title.alternative | Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-gamma- and TNF-a-co-producing T cell-mediated antitumor immunity | - |
dc.type | Conference | - |
dc.contributor.affiliatedAuthor | Yun, C-O | - |
dc.identifier.wosid | 000328417900500 | - |
dc.identifier.bibliographicCitation | Collaborative Congress of the European-Society-for-Gene-and-Cell-Therapy and the Spanish-Society-for-Gene-and-Cell-Therapy, pp.A165 | - |
dc.relation.isPartOf | Collaborative Congress of the European-Society-for-Gene-and-Cell-Therapy and the Spanish-Society-for-Gene-and-Cell-Therapy | - |
dc.relation.isPartOf | HUMAN GENE THERAPY | - |
dc.citation.title | Collaborative Congress of the European-Society-for-Gene-and-Cell-Therapy and the Spanish-Society-for-Gene-and-Cell-Therapy | - |
dc.citation.startPage | A165 | - |
dc.citation.endPage | A165 | - |
dc.citation.conferencePlace | US | - |
dc.citation.conferencePlace | Madrid, SPAIN | - |
dc.citation.conferenceDate | 2013-10-25 | - |
dc.type.rims | CONF | - |
dc.description.journalClass | 1 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.